Why Is Convatec Group Plc Up Today?

Convatec Group Plc (LSE:CTEC) shares rose 0.71% to 255.8p today. The modest gain comes after first-half 2026 results that showed 5.0% organic growth excluding InnovaMatrix, a higher Interim Dividend and a new $200 million share buyback.

The medical products group also narrowed its full-year organic growth guidance to 5.5% to 6.5% and confirmed an adjusted Operating Margin of at least 23.0%.

At the same time, reported profit was reduced by a non-cash Impairment linked to InnovaMatrix, which helps explain a measured share price response.

About Convatec Group Plc

Convatec Group Plc is a global medical products and technologies company focused on chronic conditions.

Its four franchises are Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care.

The group sells products used by patients and healthcare professionals in areas such as wound management, ostomy, urology and diabetes-related infusion.

Jonny Mason is Chief Executive Officer, and the company is executing its Accelerate strategy announced in April 2026.

Key Reasons Behind Today's Uptick

Today's 0.71% rise is modest and reflects a mix of positive and cautionary signals in the latest results.

Positive factors include organic growth excluding InnovaMatrix of 5.0%, a 15.4% increase in the interim dividend and the new $200 million buyback.

Investors are also weighing the impact of InnovaMatrix, where Revenue fell 94% to $2 million after US reimbursement changes, and the rise in net debt.

Healthcare stocks are often viewed as defensive, but they remain sensitive to reimbursement policy, cost Inflation and currency movements.

H1 2026 Financial Performance

Convatec reported revenue of $1,232 million, up 4.4% on a reported basis. Organic growth was 1.8%, or 5.0% excluding InnovaMatrix.

Adjusted operating profit increased 3.9% to $262 million, with an adjusted operating margin of 21.2%. In constant currency, the margin improved by 50 basis points.

Adjusted diluted EPS rose 6.3% to 8.5 cents.

Reported operating profit fell 36.1% to $115 million and reported diluted EPS was 2.7 cents, reflecting a $69 million non-cash impairment related to InnovaMatrix.

Franchise Performance

Excluding InnovaMatrix, Infusion Care was the fastest-growing franchise, with organic growth of 7.4% on revenue of $246 million.

Continence Care grew 5.9% to $277 million and Ostomy Care increased 4.3% to $353 million.

Advanced Wound Care grew 3.4% to $354 million excluding InnovaMatrix.

The spread across franchises shows that the core portfolio is growing, and LSE:CTEC's results depend on maintaining that momentum while the InnovaMatrix issue is absorbed.

The InnovaMatrix Reset

InnovaMatrix revenue declined to $2 million after US reimbursement changes. The reported results include a $69 million non-cash charge, comprising $48 million of intangible impairment and a $21 million expected Credit loss provision.

Management now expects InnovaMatrix revenue of $5 million to $10 million in 2026, compared with its previous expectation of about $20 million.

Reimbursement changes in the US show how policy decisions can quickly alter the outlook for a product line.

By excluding InnovaMatrix, the company is giving investors a clearer view of the performance of the rest of the portfolio.

Dividend and Share Buyback

Convatec announced an interim dividend of 2.166 cents per share, up 15.4%.

It also launched a new $200 million share buyback, to be completed by 31 December 2026. This follows a $300 million buyback in 2025.

Together, the dividend increase and buyback show a commitment to returning cash to shareholders.

These returns must be balanced against Leverage and Investment needs, as net Debt rose in the half.

Cash Flow and Balance Sheet

Free Cash Flow to shareholders was $22 million in H1, compared with $98 million a year earlier, and cash conversion was 12.9%.

Capital expenditure was $128 million in the half, including $90 million of growth investment.

Net debt excluding leases rose to $1,534 million from $1,330 million at the end of 2025, and leverage was 2.3 times adjusted EBITDA.

The company is targeting leverage of about 2.0 times by year-end and expects cash conversion of around 100% for the full year.

Lower cash generation in the half was a key reason leverage rose, so improvement is needed in the second half.

2026 Guidance

Convatec narrowed its organic revenue growth guidance excluding InnovaMatrix to 5.5% to 6.5%, from 5% to 7%. It expects growth of 6% to 8% in the second half.

The adjusted operating margin is expected to be at least 23.0%, including about 40 basis points of currency headwind, and adjusted EPS growth is expected to be double-digit.

Capital expenditure is guided to $200 million to $230 million, including $135 million to $165 million of growth capex.

The adjusted tax rate is expected to be around 23%, and adjusted net finance expense $70 million to $75 million.

Accelerate Strategy and Product Pipeline

The Accelerate strategy targets organic revenue growth of 6% to 8% a year from 2027 and an adjusted operating margin of 24% to 26%, with a mid-20s margin by 2027.

The company also targets double-digit adjusted EPS growth and double-digit growth in free cash flow.

In wound care, ConvaNiox has launched in limited European markets and was added to the UK Drug Tariff in July 2026. ConvaVAC received initial US clearance in July 2026, with a full launch expected in 2027.

Other launches include Aquacel ConvaFiber in Germany in H2 2026, GentleCath Air Pocket and Set later in 2026, and Natura Body and Flexi-Seal Air in 2027.

Pipeline Details and Regulatory Milestones

ConvaNiox was added to the UK Drug Tariff in July 2026 at £40 per dressing. A US de novo submission to the FDA is planned, and a randomised controlled trial is expected to publish in 2027.

ConvaVAC has launched in limited European markets and received initial US clearance, with a full launch expected in 2027.

Esteem Body, an ostomy product, has annualised revenue of about $60 million and roughly 15% share of its segment, showing how new products can build scale.

Regulatory outcomes and reimbursement decisions will influence how quickly these launches contribute to LSE:CTEC's growth.

Sector and Economic Exposure

Convatec operates in healthcare markets where Demand is driven by ageing populations and the prevalence of chronic conditions.

Its Earnings are linked to hospital procurement, reimbursement frameworks and clinician adoption of new products.

Currency movements are important because the company reports in US dollars but sells across many regions.

Input costs, Supply chains and regulatory approvals also affect margins and launch timing.

Margin and Earnings Progress

Adjusted operating profit grew 3.9% in the half, below the rate of organic growth excluding InnovaMatrix, partly because of currency effects.

In constant currency, the adjusted operating margin improved by 50 basis points, which supports the full-year target of at least 23.0%.

Adjusted EPS growth of 6.3% in H1 compares with guidance for double-digit growth over the full year, so second-half delivery will be important.

Management also expects the Leverage Ratio to move back toward about 2.0 times by year-end.

Key Risks to Watch

Reimbursement changes, as seen with InnovaMatrix, are a significant risk for medical device companies.

Free cash flow was lower in the first half and net debt increased, so cash conversion in the second half will be important.

The guidance for 6% to 8% organic growth in H2 requires an acceleration from the first-half rate of 5.0% excluding InnovaMatrix.

Product launches also carry execution risk, including regulatory timing and commercial adoption.

Conclusion

Convatec Group Plc shares rose 0.71% to 255.8p today, following first-half results that showed 5.0% organic growth excluding InnovaMatrix and a 15.4% higher interim dividend.

The group launched a new $200 million buyback and narrowed its 2026 guidance, while a $69 million non-cash impairment weighed on reported profit.

For investors following LSE:CTEC, the main themes are second-half acceleration, cash conversion, leverage and delivery of the Accelerate strategy.